Terms: = Ovarian cancer AND PALB2, ENSG00000083093, 79728 AND Prognosis
11 results:
1. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
2. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.
Bhattacharya R; Ghosh A; Mukhopadhyay S
Mol Biol Rep; 2023 Nov; 50(11):9511-9519. PubMed ID: 37737967
[TBL] [Abstract] [Full Text] [Related]
3. The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
Li Y; Chen Z; Peng J; Yuan C; Yan S; Yang N; Li P; Kong B
Oncogene; 2023 Jul; 42(31):2386-2401. PubMed ID: 37391593
[TBL] [Abstract] [Full Text] [Related]
4. Potential prognostic role of somatic mutations in a set of cancer susceptibility genes in ovarian carcinoma: A follow-up multicentric study from Pakistan.
Masood A; Sarfaraz R; Zaki S; Shami A; Khaliq S; Naseem N
Cancer Biomark; 2023; 36(3):207-219. PubMed ID: 36776043
[TBL] [Abstract] [Full Text] [Related]
5. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract] [Full Text] [Related]
6. New Perspectives on the Recurrent Monoallelic Germline Mutations of DNA Repair and Checkpoint Genes and Clinical Variability.
Sahin I; Saat H
Genet Test Mol Biomarkers; 2022 Jan; 26(1):17-25. PubMed ID: 35089076
[No Abstract] [Full Text] [Related]
7. Hereditary pancreatic cancer.
Abe K; Kitago M; Kitagawa Y; Hirasawa A
Int J Clin Oncol; 2021 Oct; 26(10):1784-1792. PubMed ID: 34476650
[TBL] [Abstract] [Full Text] [Related]
8. [palb2, a major susceptibility gene for breast cancer].
Piffer A; Luporsi E; Mathelin C
Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):701-705. PubMed ID: 30243941
[TBL] [Abstract] [Full Text] [Related]
9. PARP Inhibitors in the Treatment of Triple-Negative Breast cancer.
Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
[TBL] [Abstract] [Full Text] [Related]
10. An integrated in silico approach to analyze the involvement of single amino acid polymorphisms in FANCD1/BRCA2-palb2 and FANCD1/BRCA2-RAD51 complex.
Doss CG; Nagasundaram N
Cell Biochem Biophys; 2014 Nov; 70(2):939-56. PubMed ID: 24817641
[TBL] [Abstract] [Full Text] [Related]
11. Familial pancreatic cancer: genetic advances.
Rustgi AK
Genes Dev; 2014 Jan; 28(1):1-7. PubMed ID: 24395243
[TBL] [Abstract] [Full Text] [Related]
